Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

CJC-1295 No DAC and Visceral Fat

Human CJC-1295 studies did not test no-DAC material for visceral fat loss, so they cannot support a starting dose or cycle.

Why we wrote this. A community question asked for a no-DAC fat-loss protocol, but the human evidence studied another molecule and another endpoint.

In this article (5 sections)
  1. The human study tested a different molecule
  2. The visceral-fat claim lacks a matching trial
  3. Why the literature cannot produce a cycle
  4. Safety uncertainty does not disappear with no DAC
  5. What this means for the original question

A reader bought CJC-1295 no DAC hoping to reduce visceral fat, then asked what dose to start with and whether to cycle it. The published evidence cannot supply either answer. The small human programme tested long-acting, albumin-binding CJC-1295, not the product commonly called CJC-1295 no DAC, and it measured growth hormone and insulin-like growth factor 1 (IGF-1) rather than abdominal fat loss[1]. A 2026 sports-medicine review found only animal evidence for the commonly discussed CJC-1295 and ipamorelin combination and said human indications and dosing remain unknown[2].

That leaves a clear practical boundary. Numbers copied from the original CJC-1295 trials are not a researched starting point for no-DAC material. Claims about reducing love handles or visceral fat also outrun the outcomes those trials recorded. This article explains the mismatch without turning an evidence gap into a protocol.

The human study tested a different molecule

The 2006 Teichman paper is the main human CJC-1295 study. Two randomized, placebo-controlled, double-blind ascending-dose trials enrolled healthy adults aged 21 to 61. After one administration, mean growth hormone rose for at least six days, mean IGF-1 rose for nine to eleven days, and the estimated half-life was 5.8 to 8.1 days. The trial followed hormone concentrations and pharmacokinetics, meaning how the investigational compound moved through the body. It did not test visceral-fat reduction, body recomposition, or cosmetic fat loss[1].

The long duration was part of the molecule's design. Earlier work described CJC-1295 as a modified growth-hormone-releasing factor that binds to serum albumin, a protein in the blood, through an added reactive group. That albumin binding was intended to extend exposure beyond the short life of ordinary growth-hormone-releasing factor[1]. Removing the drug affinity complex, or DAC, removes the defining feature of the compound studied in the human programme.

Anti-doping researchers make the naming problem visible. A 2021 analytical paper listed CJC-1295 and CJC-1295 with drug affinity complex as separate targets when developing a urine-detection method[3]. That does not establish how no-DAC material performs in people, but it does show why results from one entry should not be assigned to the other merely because sellers use a shared name. Our with-DAC versus without-DAC explainer covers the chemistry in more detail.

The visceral-fat claim lacks a matching trial

Visceral adipose tissue is fat stored around the abdominal organs. It is not the same measurement as waist appearance or a pinchable love handle. The Teichman trials did not report either outcome. Their endpoints were circulating CJC-1295, growth hormone, and IGF-1[1]. A rise in those laboratory markers is not itself proof of fat loss, and the paper did not enroll people seeking treatment for excess abdominal fat.

Tesamorelin can make the source of some online confusion easier to see. It is another growth-hormone-releasing factor analogue, but it has a specific FDA-approved product and a specific population. The Egrifta WR label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. The same label says it is not indicated for weight-loss management and has a weight-neutral effect[4]. Evidence for tesamorelin in that narrow condition does not establish a visceral-fat benefit for CJC-1295 no DAC in otherwise healthy people.

The 2026 review by Mayfield and colleagues looked directly at injectable peptides discussed in orthopaedic and sports-medicine settings. For CJC-1295 combined with ipamorelin, it found improved muscle-force measurements in mice with glucocorticoid-induced muscle loss. The authors explicitly limited that finding to animal work and concluded that substantial safety and efficacy research is still needed before recommendations can be made[2]. That is not a human visceral-fat study, and adding ipamorelin makes it still less applicable to no-DAC CJC-1295 used alone.

Why the literature cannot produce a cycle

A dose in an early pharmacology trial answers a narrow research question: what exposure and hormone response occurred with that defined compound under observation. It does not establish a treatment schedule for another molecule or another goal. In the Teichman programme, the compound was the albumin-binding version, the participants were healthy volunteers, and the follow-up lasted 28 or 49 days[1]. Those facts block a responsible conversion into a no-DAC fat-loss cycle.

Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.

Mayfield et al., American Journal of Sports Medicine, 2026[2]

The review's wording is useful because it keeps four unanswered questions together. An indication identifies the condition being treated. Dosing and frequency define exposure. Duration sets the observation window for benefits and harms. Community schedules often supply all four by assertion even though the clinical literature has not done the underlying work[2].

Safety uncertainty does not disappear with no DAC

The FDA lists CJC-1295 among bulk drug substances withdrawn from nomination after placement in a category for substances that may present significant safety risks in compounding. The agency says compounded CJC-1295 may pose immunogenicity risk, meaning an unwanted immune response, and may have peptide-impurity and ingredient-characterization problems. It also identifies reports of increased heart rate and a systemic vasodilatory reaction, while stressing that the available clinical data are limited[5].

That FDA summary does not separate with-DAC from no-DAC products, so it cannot tell us that the two versions have identical risks. It does show why a shorter-acting label should not be treated as a safety finding. Faster clearance, even if a vial contains the molecule claimed, does not answer questions about impurities, immune reactions, repeated exposure, or long-term effects. The CJC-1295 regulation section tracks the current status without offering a sourcing route.

What this means for the original question

The evidence supports three restrained conclusions. The main human CJC-1295 results belong to the long-acting albumin-binding compound. Those trials measured hormone responses rather than visceral-fat loss. Current sports-medicine reviewers still describe the clinical indications and dosing of popular injectable peptide approaches as unknown[1][2]. None of those conclusions yields a starting amount, cycle length, or expectation for love-handle reduction from no-DAC material.

A qualified clinician can help distinguish visceral fat from subcutaneous fat and assess whether either is a medical concern. That conversation can use validated measurements and an approved treatment pathway when one applies. A vial purchased before the research was done is not evidence that using it is the next step.

Frequently asked

Does CJC-1295 no DAC reduce visceral fat?

No controlled human trial cited here tested CJC-1295 no DAC for visceral-fat reduction. The main human CJC-1295 programme studied the long-acting albumin-binding compound and measured growth hormone, IGF-1, and pharmacokinetics rather than abdominal-fat outcomes.

Can the original CJC-1295 study doses be used for no DAC?

The study doses belong to a different, albumin-binding investigational compound. They were used to measure exposure and hormone response in healthy volunteers, not to create a self-use schedule for no-DAC material or fat loss.

Why is tesamorelin evidence not proof for CJC-1295?

Tesamorelin has an FDA-approved product for reducing excess abdominal fat in adults with HIV and lipodystrophy. That narrow indication, defined product, and studied population do not establish that CJC-1295 no DAC reduces visceral fat in otherwise healthy people.

Sources

  1. [1]Teichman et al. (2006): Prolonged GH and IGF-I stimulation by long-acting CJC-1295 in healthy adults (PMID 16352683)Tier 1 · primary↩
  2. [2]Mayfield et al. (2026): Injectable peptide therapy primer for orthopaedic and sports medicine physicians (PMID 41476424)Tier 1 · primary↩
  3. [3]Memdouh et al. (2021): Detection of CJC-1295 and CJC-1295 with drug affinity complex as separate GHRH analogues (PMID 34665524)Tier 1 · primary↩
  4. [4]FDA prescribing information for Egrifta WR (tesamorelin), revised March 2025Tier 1 · primary↩
  5. [5]FDA: Bulk drug substances for compounding that may present significant safety risksTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars